Literature DB >> 8226152

Primary radiation therapy for endometrial carcinoma: a case controlled study.

P G Rose1, S Baker, M Kern, T J Fitzgerald, W K Tak, F R Reale, B E Nelson, R E Hunter.   

Abstract

PURPOSE: Primary radiation therapy is generally considered inferior to a surgical approach for patients with endometrial carcinoma and is reserved for patients with a high operative risk. These patients are usually elderly, have multiple medical problems and frequently die of intercurrent disease. To evaluate the efficacy of primary radiation therapy a case controlled analysis comparing corrected survival of patients treated with primary radiation to patients treated with surgical therapy with or without radiation therapy was performed. METHODS AND MATERIALS: Sixty-four patients treated with primary radiation therapy were retrospectively studied. A Kaplan-Meier product limit survival analysis was used to estimate survival among patients treated with primary radiation therapy. A case control study matched by clinical stage, tumor grade, and time of diagnosis was performed. The Mantel-Cox statistic was used to evaluated the equality of the survival curves.
RESULTS: Primary radiation therapy was used to treat 9.0% of the patients with endometrial carcinoma during the study period. Cardiovascular disease, diabetes, age greater than 80 and morbid obesity were the most common indications. Ninety percent of patients had either Stage I or II disease. Forty-eight of the 64 patients (75%) completed treatment which included both teletherapy and brachytherapy. Ten patients received brachytherapy only. Twelve complications, both acute and chronic, occurred in eleven patients (17%). Intercurrent disease accounted for 13 of the 36 (36%) of the deaths. Clinical stage of disease and histologic grade of the tumor were significant predictors of survival, p = 0.0001 and p = 0.013, respectively. The case controlled study of Stage I and II patients treated by primary radiation therapy matched to surgically treated controls showed no statistical difference in survival. Dilatation and curettage after the completion of radiation therapy was predictive of local control, p = 0.003.
CONCLUSION: Although surgery followed by tailored radiation therapy has become widely accepted therapy for Stage I and II endometrial carcinoma, even in patients who are a poor operative risk, the survival with primary radiation therapy is not statistically different.

Entities:  

Mesh:

Year:  1993        PMID: 8226152     DOI: 10.1016/0360-3016(93)90383-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer.

Authors:  P Dankulchai; J Petsuksiri; Y Chansilpa; P J Hoskin
Journal:  Br J Radiol       Date:  2014-05-08       Impact factor: 3.039

2.  Definitive radiotherapy for medically inoperable early-stage serous and clear cell uterine carcinoma.

Authors:  Emma C Batchelor; John M Watkins; Joseph M Jenrette
Journal:  Radiat Med       Date:  2007-12-25

Review 3.  Primary brachytherapy as a radical treatment for endometrial carcinoma.

Authors:  Elzbieta van der Steen-Banasik
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

4.  Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.

Authors:  Qian Zhou; Cheng Tang; Ke-Wei Zhao; Yan-Li Xiong; Shu Chen; Wen-Jing Xu; Xin Lei
Journal:  Clinics (Sao Paulo)       Date:  2016-01       Impact factor: 2.365

5.  Carbon-ion radiotherapy for inoperable endometrial carcinoma.

Authors:  Daisuke Irie; Noriyuki Okonogi; Masaru Wakatsuki; Shingo Kato; Tatsuya Ohno; Kumiko Karasawa; Hiroki Kiyohara; Daijiro Kobayashi; Hiroshi Tsuji; Takashi Nakano; Tadashi Kamada; Makio Shozu
Journal:  J Radiat Res       Date:  2018-05-01       Impact factor: 2.724

6.  Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it.

Authors:  Jeanine N Staples; Lisa Rauh; M Sean Peach; William D Baker; Susan C Modesitt
Journal:  Gynecol Oncol Rep       Date:  2018-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.